India approves Biocon's Herceptin biosimilar

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said the Drugs Controller General of India approved its biosimilar of Herceptin trastuzumab to treat HER2-positive, metastatic breast cancer. The company plans to launch the product in India as Canmab next quarter. Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit market Herceptin, a humanized mAb against HER2. According to Biocon, Herceptin's 2012 sales in India were $21 million. ...